— Know what they know.
Not Investment Advice
Also trades as: 300347.SZ (SHZ) · $vol 183M · 3347.HK (HKSE) · $vol 11M

HNGZY OTC

Hangzhou Tigermed Consulting Co., Ltd
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +11.2% 1Y: +11.2% 3Y: -59.8%
$4.45
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 50 · $6.9B mcap · 626M float · 0.0000% daily turnover

Cash Flow Trends

Operating Cash Flow
$1.1B -4.6% ▼
5Y CAGR: +15.8%
Capital Expenditures
$357M -13.6% ▼
5Y CAGR: +28.2%
Free Cash Flow
$740M -11.5% ▼
5Y CAGR: +11.8%
Dividends Paid
$642M -8.9% ▼
Buybacks
$271M -807.5% ▼
Net Change in Cash
-$5.4B -1298.0% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
— Operating Activities —
Net Income$2.0B$3.4B$2.3B$2.0B$448M
Depreciation & Amort.$145M$189M$265M$306M$324M
Stock-Based Comp.$31M$83M$47M$0$0
Change in Working Capital$16M-$191M-$699M-$849M-$268M
Other Non-Cash Items-$1.3B-$2.1B-$527M-$274M$594M
Operating Cash Flow$999M$1.4B$1.4B$1.2B$1.1B
— Investing Activities —
Capital Expenditures-$156M-$369M-$449M-$314M-$357M
Acquisitions (Net)-$189M-$251M-$663M-$357M-$367M
Investment Purchases-$2.9B-$3.2B-$2.2B-$2.1B-$6.2B
Investment Sales$1.0B$1.1B$430M$1.2B$2.2B
Other Investing-$161M-$38M$95M-$257M$10M
Investing Cash Flow-$2.4B-$2.8B-$2.8B-$1.9B-$4.7B
— Financing Activities —
Net Debt Issuance-$903M$492M$1.5B$684M-$501M
Stock Repurchased-$4M-$516M-$427M-$30M-$271M
Dividends Paid-$208M-$262M-$432M-$590M-$642M
Other Financing$10.5B-$394M$180M-$72M-$289M
Financing Cash Flow$9.3B-$163M$809M-$8M-$1.7B
Net Change in Cash$7.9B-$1.6B-$596M-$383M-$5.4B
Cash End of Period$10.0B$8.4B$7.8B$7.4B$2.0B
Free Cash Flow$842M$1.1B$909M$837M$740M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms